Biofrontera Inc. today announced financial results for the three and 12 months ended December 31, 2021, and provided a business update.
Introduces 2022 financial guidance
Conference call begins at 11:00a.m. Eastern time today
WOBURN, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the “Company”), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced financial results for the three and 12 months ended December 31, 2021, and provided a business update.
Financial Highlights
- Total revenues for the fourth quarter of 2021 were $9.2 million, an increase of 7% from the prior year
- Total revenues for 2021 were $24.1 million, an increase of 28% from the prior year
- Cash and cash equivalents were $24.5 million as of December 31, 2021
- Raised gross proceeds of $18 million from an initial public offering (IPO) and $15 million from a subsequent private placement
- Raised $13 million from the exercise of outstanding warrants, reducing Biofrontera AG’s ownership of Biofrontera Inc. to less than 50%
Clinical and OperationalHighlights
- Initiated two clinical studies to expand the Ameluz® photodynamic therapy (PDT) market opportunity in the U.S.
- Enrolled the first subject in a Phase 1 safety study evaluating PDT with three tubes of Ameluz®
- Enrolled the first subject in a Phase 2b study evaluating Ameluz® + BF-RhodoLED® (Ameluz®-PDT) in moderate-to-severe acne
- Continued recruitment of subjects in a Phase 3 study evaluating Ameluz®-PDT for the treatment of basal cell carcinoma
- Appointed Kevin Weber, a pharmaceutical executive with more than 30 years of executive and commercial experience, to the Company’s Board of Directors
- Received notices of allowance for U.S. patents on a PDT illumination protocol and an illumination device
- Received U.S. regulatory clearance for the RhodoLED® XL lamp
- Received Orange Book listing for a RhodoLED® XL lamp patent, providing Ameluz®-PDT with protection from generic competition through October 2040
Management Commentary
“2021 was a foundational year for Biofrontera Inc. From completing our IPO in October to laying the groundwork for expanding the label of our flagship product Ameluz®, I’m proud of the hard work by our team in executing Biofrontera’s strategic vision. We entered 2022 with the capital, commercial momentum and strategic plan in place to build shareholder value,” said Erica Monaco, Chief Executive Officer of Biofrontera Inc.
“Despite continued challenges resulting from the COVID-19 pandemic, we returned to topline growth in 2021 and sales have now recovered to near pre-pandemic levels including a seasonally strong fourth quarter. In 2021 we increased our market share within the PDT drug segment to approximately 26%, up from approximately 24% in the previous year. We expect the momentum established in 2021 will continue to drive revenue growth from top customer accounts as the opportunity to gain share from cryotherapy remains a key focus of our commercial efforts. Our goal is to continue to improve the market positioning of Ameluz® to become the leading PDT drug for the treatment of actinic keratosis (AK) in the United States,” she added.
Fourth Quarter Financial Results
Total revenues were $9.2 million and $8.6 million for the three months ended December 31, 2021 and 2020, respectively, an increase of $0.6 million, or 7%.
Total operating expenses were $11.0 million and $8.8 million for the three months ended December 31, 2021 and 2020, respectively. Cost of revenues increased by 8% primarily due to higher sales of Ameluz®. Selling, general and administrative expenses increased by $5.1 million compared with the prior year primarily due to an increase in marketing expenses and headcount.
Net loss was $14.5 million and $0.2 million for the three months ended December 31, 2021 and 2020, respectively.
Adjusted EBITDA was negative $3.2 million and negative $3 thousand for the three months ended December 31, 2021 and 2020, respectively. Adjusted EBITDA, a non-GAAP financial measure, is defined as net income or loss excluding interest income and expense, income taxes, depreciation and amortization, legal settlement expense and certain other non-recurring or non-cash items.
Full Year Financial Results
Total revenues were $24.1 million and $18.8 million for 2021 and 2020, respectively, an increase of $5.3 million, or 28%. The increase was primarily driven by a higher volume of Ameluz® orders, which increased Ameluz® revenue by $4.1 million, and by an increase in the price of Ameluz®, which increased Ameluz® revenue by $1.3 million.
Total operating expenses were $49.3 million and $28.5 million for 2021 and 2020, respectively. Cost of revenues increased by $3.7 million compared with the prior year primarily due to higher sales of Ameluz®. Selling, general and administrative expenses increased by $19.1 million compared with the prior year primarily due to a one-time legal settlement expense, marketing campaign expenses, increased headcount and higher commission expenses related to improved sales performance.
Net loss was $37.7 million and $11.0 million for the years ended December 31, 2021 and 2020, respectively.
Adjusted EBITDA was negative $12.7 million for the year ended December 31, 2021 and was negative $9.2 million for the year ended December 31, 2020.
The table below presents a reconciliation from net loss to Adjusted EBITDA for the three and 12 months ended December 31, 2021 and 2020:
| Quarters ended December 31, | Years ended December 31, | ||||||||||||||||
| 2021 | 2020 | 2021 | 2020 | ||||||||||||||
| Net income/(loss) | $ | (14,505 | ) | $ | (186 | ) | $ | (37,713 | ) | $ | (10,987 | ) | |||||
| Interest expense, net | 89 | 756 | 344 | 2,869 | |||||||||||||
| Income tax expenses | 5 | (2 | ) | 56 | 64 | ||||||||||||
| Depreciation and amortization | 131 | 138 | 540 | 562 | |||||||||||||
| EBITDA | (14,280 | ) | 706 | (36,773 | ) | (7,492 | ) | ||||||||||
| Change in fair value of contingent consideration | (3,100 | ) | (98 | ) | (1,402 | ) | 140 | ||||||||||
| Change in fair value of warrant liabilities | 12,801 | - | 12,801 | - | |||||||||||||
| Cost reimbursement from Biofrontera Pharma GmbH | - | (312 | ) | - | (1,500 | ) | |||||||||||
| Legal settlement expenses | - | - | 11,250 | - | |||||||||||||
| Employee retention credit (“ERC”) | - | (299 | ) | - | (299 | ) | |||||||||||
| Expensed issuance costs | 1,383 | - | 1,383 | - | |||||||||||||
| Adjusted EBITDA | $ | (3,196 | ) | $ | (3 | ) | $ | (12,741 | ) | $ | (9,151 | ) | |||||
| Adjusted EBITDA margin | -34.9 | % | 0.0 | % | -52.9 | % | -48.5 | % | |||||||||
Cash and cash equivalents as of December 31, 2021 were $24.5 million, compared with $8.1 million as of December 31, 2020. During 2021, Biofrontera received net proceeds of $41.8 million including $14.9 million from the sale of common stock in its IPO, $13.6 million from a private placement and $13.2 million from warrants exercised for its common stock. The Company believes its cash and cash equivalents are sufficient to fund its operations for at least the next 12 months.
Financial Guidance
Biofrontera today introduced financial guidance for 2022, as follows:
- Total revenues are expected to increase by at least 30% compared with 2021, including first quarter total revenues up by over 100% versus the first quarter prior year and typical seasonal strength in the first and fourth quarters
- The commercial focus throughout 2022 will be on achieving deeper sales penetration among current customer accounts, with additions to the Biofrontera sales force expected to begin in 2023
Conference Call and Webcast
Biofrontera Inc. will hold a conference call today at 11:00 a.m. Eastern time to discuss these results and answer questions.
| Date: | Friday, April 8, 2022 | |
| Time: | 11:00 a.m. Eastern time | |
| Conference Call: | 1-877-877-1275 (U.S.) | |
| 1-412-858-5202 (international) | ||
| Webcast: | Live and 90-day replay webcast are available here and at www.investors.biofrontera-us.com. |
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the Company’s business and marketing strategy, future operations and business, future financial position, potential to expand the label of Ameluz®, expected revenue growth, expected cash flow for operations, expected total revenues, projections constituting the financial guidance included in this release and statements about the commercial focus of Biofrontera Inc. throughout the year and expected increases in the Company’s sales force. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of extraordinary external events, such as the current COVID-19 pandemic; any changes in the Company’s relationship with its licensors; the ability of the Company’s licensors to fulfill their obligations to the Company in a timely manner; the Company’s ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company’s ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company’s licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz® in combination with BF-RhodoLED® in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz® in combination with BF-RhodoLED® is consistent with the Company’s expectations; the Company’s ability to complete the transition to a public company; the Company’s ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company’s filings with the SEC, which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management’s current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Contacts:
Biofrontera Inc.
Anke zur Mühlen
+1 781 486 1539
us-ir@biofrontera.com
LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
tpatel@lhai.com
(Tables to follow)
BIOFRONTERA INC.
BALANCE SHEETS
(In thousands, except par value and share amounts)
| December 31, | ||||||||
| 2021 | 2020 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 24,545 | $ | 8,080 | ||||
| Accounts receivable, net | 3,784 | 3,216 | ||||||
| Other receivables, related party | 8,647 | 73 | ||||||
| Inventories | 4,458 | 7,091 | ||||||
| Prepaid expenses and other current assets | 4,987 | 1,116 | ||||||
| Total current assets | 46,421 | 19,576 | ||||||
| Other receivables long term, related party | 2,813 | - | ||||||
| Property and equipment, net | 267 | 370 | ||||||
| Intangible asset, net | 3,450 | 3,869 | ||||||
| Other assets | 268 | 323 | ||||||
| Total assets | $ | 53,219 | $ | 24,138 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 658 | $ | 176 | ||||
| Accounts payable, related parties | 282 | 1,538 | ||||||
| Acquisition contract liabilities, net | 3,242 | - | ||||||
| Accrued expenses and other current liabilities | 9,654 | 2,706 | ||||||
| Total current liabilities | 13,836 | 4,420 | ||||||
| Long-term liabilities: | ||||||||
| Acquisition contract liabilities, net | 9,542 | 13,828 | ||||||
| Warrant liabilities | 12,854 | - | ||||||
| Other liabilities | 5,649 | 62 | ||||||
| Total liabilities | $ | 41,881 | $ | 18,310 | ||||
| Commitments and contingencies (see Note 23) | ||||||||
| Stockholders’ equity: | ||||||||
| Common Stock, $0.001 par value, 300,000,000 shares authorized; 17,104,749 and 8,000,000 shares issued and outstanding as of December 31, 2021 and 2020 | $ | 17 | $ | 8 | ||||
| Additional paid-in capital | 90,200 | 46,986 | ||||||
| Accumulated deficit | (78,879 | ) | (41,166 | ) | ||||
| Total stockholders’ equity | 11,338 | 5,828 | ||||||
| Total liabilities and stockholders’ equity | $ | 53,219 | $ | 24,138 | ||||
BIOFRONTERA INC.
STATEMENTS OF OPERATIONS
(In thousands, except per share amounts and number of shares)
| Year Ending December 31, | |||||||||
| 2021 | 2020 | ||||||||
| Products revenues, net | $ | 24,043 | $ | 18,787 | |||||
| Revenues, related party | 57 | 62 | |||||||
| Total revenues, net | 24,100 | 18,849 | |||||||
| Operating expenses | |||||||||
| Cost of revenues, related party | 12,222 | 8,313 | |||||||
| Cost of revenues, other | 520 | 753 | |||||||
| Selling, general and administrative | 36,512 | 17,706 | |||||||
| Selling, general and administrative, related party | 697 | 411 | |||||||
| Restructuring costs | 752 | 1,132 | |||||||
| Change in fair value of contingent consideration | (1,402 | ) | 140 | ||||||
| Total operating expenses | 49,301 | 28,455 | |||||||
| Loss from operations | (25,201 | ) | (9,606 | ) | |||||
| Other income (expense) | |||||||||
| Change in fair value of warrant liabilities | (12,801 | ) | - | ||||||
| Interest expense, net | (344 | ) | (2,869 | ) | |||||
| Other income, net | 689 | 1,552 | |||||||
| Total other income (expense) | (12,456 | ) | (1,317 | ) | |||||
| Loss before income taxes | (37,657 | ) | (10,923 | ) | |||||
| Income tax expense | 56 | 64 | |||||||
| Net loss | $ | (37,713 | ) | $ | (10,987 | ) | |||
| Loss per common share: | |||||||||
| Basic and diluted | $ | (4.28 | ) | $ | (479.48 | ) | |||
| Weighted-average common shares outstanding: | |||||||||
| Basic and diluted | 8,808,233 | 22,915 | |||||||
# # #
BIOFRONTERA INC.
STATEMENTS OF OPERATIONS
(In thousands, except per share amounts and number of shares)
| Quarters Ended December 31, | ||||||||||
| 2021 | 2020 | |||||||||
| Products revenues, net | $ | 9,153 | $ | 8,557 | ||||||
| Revenues, related party | 15 | 15 | ||||||||
| Total revenues, net | 9,168 | 8,572 | ||||||||
| Operating expenses | ||||||||||
| Cost of revenues, related party | 4,592 | 4,288 | ||||||||
| Cost of revenues, other | 181 | 135 | ||||||||
| Selling, general and administrative | 9,100 | 4,149 | ||||||||
| Selling, general and administrative, related party | 177 | 14 | ||||||||
| Restructuring costs | 98 | 272 | ||||||||
| Change in fair value of contingent consideration | (3,100 | ) | (98 | ) | ||||||
| Total operating expenses | 11,048 | 8,760 | ||||||||
| Loss from operations | (1,880 | ) | (188 | ) | ||||||
| Other income (expense) | ||||||||||
| Change in fair value of warrant liabilities | (12,801 | ) | - | |||||||
| Interest expense, net | (89 | ) | (756 | ) | ||||||
| Other income, net | 270 | 756 | ||||||||
| Total other income (expense) | (12,620 | ) | (0 | ) | ||||||
| Loss before income taxes | (14,500 | ) | (188 | ) | ||||||
| Income tax expense | 5 | (2 | ) | |||||||
| Net loss | $ | (14,505 | ) | $ | (186 | ) | ||||
| Loss per common share: | ||||||||||
| Basic and diluted | $ | (1.29 | ) | $ | (2.12 | ) | ||||
| Weighted-average common shares outstanding: | ||||||||||
| Basic and diluted | 11,206,578 | 87,946 | ||||||||
